We use cookies to make your experience better. To comply with the new e-Privacy directive, we need to ask for your consent to set the cookies. Learn more.
Irvine Scientific Introduces Chemically-Defined Dendritic Cell Culture Medium for Immunotherapy Applications
Dendritic cells are a key contributor to developing cancer vaccines
SANTA ANA, California – September 19, 2017: Irvine Scientific, a world leader in cell culture media development and manufacture, today announced the introduction of PRIME-XV Dendritic Cell Maturation CDM, a chemically-defined, animal component-free medium for the differentiation of monocytes into immature dendritic cells, and subsequent maturation in dendritic cells.
Current approaches to immunotherapy include harnessing the power of the body’s immune system to treat tumors with cell therapies. One approach is through vaccination, a method where an antigen together with an adjuvant stimulates the body to create therapeutic T cells. Dendritic cells (DCs) are the most potent antigen-presenting cells capable of priming naïve T cells and are therefore essential tools in the activation of immune responses to tumors. They can be generated in vitro from CD14+ peripheral blood or cord blood monocytes through a maturation process. It is essential for these monocyte-derived DCs (Mo-DCs) to maintain their functional capacity of the launching antigen-specific immunity, leading to T cell activation into therapeutic T cells. Serum and undefined components found in animal- or human-derived raw materials can negatively affect this Mo-DC functional capacity. PRIME-XV Dendritic Cell Maturation CDM provides a robust method for the generation of Mo-DCs in chemically-defined culture conditions, thereby maintaining their capacity to induce T cell response.
“Our continuous research on the effects of components in media has produced convincing data that culturing cells in chemically-defined conditions improves the ability to reliably produce populations of cells that maintain desired functionality and morphology compared to culture media containing animal-derived components,” said Jessie H.-T. Ni, Chief Scientific Officer, Irvine Scientific. “Chemically-defined media also reduces the risk of introducing foreign agents or impurities from undefined components, thereby facilitating scale-up to commercial production and the regulatory submission process.”
PRIME-XV Dendritic Cell Maturation CDM is the ideal complement to PRIME-XV T Cell CDM, the first commercially available chemically-defined medium for T cell culture. Together they provide a complete workflow free from the variability and risk of contamination that the use of animal-derived components presents. All products are manufactured using stringent raw material qualification and under Current Good Manufacturing Practices (cGMP) for consistency and reliability.
About Irvine Scientific
Irvine Scientific, a member of JXTG Group, is a worldwide leader in the innovation and manufacture of cell culture media, reagents, and medical devices for researchers and clinicians. The company provides unrivalled service and quality to scientists working in cell therapy and regenerative medicine, assisted reproductive technology and cytogenetics, and industrial cell culture for the large-scale production of biotherapeutics and vaccines. Irvine Scientific adheres to both ISO and FDA regulations and operates dual cGMP manufacturing facilities in California, USA and Tokyo, Japan. The company’s consultative philosophy combined with expertise in cell culture and compliance provides customers with unique capabilities and support. For over 45 years, Irvine Scientific has remained uniquely flexible and focused on media while becoming a strategic global leader in media products and services.
Media contacts:
Lori Serles, Irvine Scientific
Phone: 949-261-7800 x145
Email: lserles@irvinesci.com
Lorna Cuddon, Zyme Communications
Phone: +44 (0)7811996942
Email: lorna.cuddon@zymecommunications.com
